Cyclophosphamide 50mg

DRUG9 trials

Conditions

Acute Lymphoblastic Leukemia (ALL) in Complete RemissionAcute Myeloid Leukemia (AML) in RemissionAdult Diffuse Large Cell LymphomaAdult Refractory Diffuse Large B-Cell LymphomaAnemia, AplasticAnemia, Sickle CellBreast CancerBreast Neoplasms

Phase 1

Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)

CompletedNCT00326417

Medical College of WisconsinAnemia, Aplastic

Start: 2006-01-31End: 2016-01-31Updated: 2021-10-28

The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma

NCT04262427

The Christie NHS Foundation TrustMetastatic Renal Cell Carcinoma

Start: 2021-04-28End: 2024-04-28Target: 21Updated: 2022-08-23

Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

Active, not recruitingNCT04895761

Providence Health & ServicesBreast Cancer

Start: 2021-09-10End: 2026-09-01Updated: 2025-03-10

Siplizumab for Sickle Cell Disease Transplant

TerminatedNCT06078696

Columbia UniversityAnemia, Sickle Cell

Start: 2023-09-28End: 2025-12-11Updated: 2026-02-27

Phase 2

Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide

CompletedNCT03139851

Centre Leon BerardMetastatic Breast Cancer

Start: 2017-06-27End: 2019-09-18Updated: 2021-09-10

DPX-Survivac and Checkpoint Inhibitor in DLBCL

CompletedNCT03349450

Sunnybrook Health Sciences CentreAdult Diffuse Large Cell Lymphoma, Adult Refractory Diffuse Large B-Cell Lymphoma, Recurrent

Start: 2018-03-13End: 2023-07-18Updated: 2023-11-02

Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer

TerminatedNCT05243524

ImmunoVaccine Technologies, Inc. (IMV Inc.)Platinum-resistant Epithelial Ovarian Cancer

Start: 2022-08-05End: 2023-08-31Updated: 2023-09-13

Phase 3

Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients

RecruitingNCT04314219

King Faisal Specialist Hospital & Research CenterAcute Lymphoblastic Leukemia (ALL) in Complete Remission, Acute Myeloid Leukemia (AML) in Remission

Start: 2021-08-15End: 2026-12-31Target: 264Updated: 2025-03-13

Unknown Phase

Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients

CompletedNCT02583828

Capital Medical UniversityBreast Neoplasms, Neoplasm Metastasis

Start: 2015-06-30End: 2021-12-31Updated: 2024-02-07

eJHaem2024-12-122 citations

Long-term survival after unrelated donor marrow transplantation for aplastic anaemia after optimized conditioning regimen: a retrospective multicentre cohort study.

2024-09-053 citations

Long-Term Outcomes after Unrelated Marrow Transplantation for Aplastic Anemia with Optimized Cyclophosphamide Dose (BMT CTN 0301)

Blood2023-11-02

Abstract OT2-20-01: Neoadjuvant survivin immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor positive (HR+) early-stage breast cancer

Cancer Research2023-03-01

72TiP AVALON trial: Phase IIb study of maveropepimut-s and low-dose cyclophosphamide in subjects with platinum-resistant, epithelial ovarian cancer

ESMO Open2023-02-01

646 Neoadjuvant immunotherapy combining maveropepimut-S (MVP-S) with letrozole decreases Ki67 and increases Th1 immune response in hormone receptor positive (HR+) early-stage breast cancer (ESBC)

Regular and Young Investigator Award Abstracts2022-11-01

Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC).

Journal of Clinical Oncology2022-06-01

PB2138: VITALIZE TRIAL: A PHASE 2B, OPEN-LABEL, MULTICENTER, RANDOMIZED PARALLEL-GROUP, TWO-STAGE, STUDY OF MAVEROPEPIMUT-S, PEMBROLIZUMAB, WITH OR WITHOUT INTERMITTENT LOW-DOSE CYCLOPHOSPHAMIDE, IN R/R DLBLC

HemaSphere2022-06-01

356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab

Regular and Young Investigator Award Abstracts2020-11-01

Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study.

2015-09-0259 citations